FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer
The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).
How this was made

The 30-second read
Why it matters
The FDA’s accelerated approval adds a new targeted option for previously treated ALK-positive NSCLC, including reported intracranial activity, but the evidence base is response and duration rather than overall survival.
Market read
Traders may reassess GSK’s oncology pipeline value and near-term sentiment for ALK NSCLC competitors, while weighing accelerated-approval uncertainty.
What to watch
Eligibility is restricted to specific prior ALK TKI histories, and the safety profile highlights hepatotoxicity monitoring needs, which could constrain uptake versus broader later-line options.
Background
Neladalkib (Nelkarmi) received Breakthrough Therapy and Orphan Drug designations and is positioned for ALK-positive NSCLC after progression on prior ALK-directed therapies.
Ticker impact
FDA granted accelerated approval to neladalkib, announced by GSK, expanding its ALK-positive NSCLC targeted therapy portfolio.
Likely modest positive bias as investors price in additional late-stage pipeline value, tempered by uncertainty around durability, confirmatory trial outcomes, and competitive positioning.
The article is a direct FDA approval event tied to GSK’s announced acquisition-linked development, but it provides no revenue guidance or confirmatory readout timing, limiting near-term earnings impact visibility.
Market effects
Reinforces continued investor interest in ALK-targeted lung cancer drugs and CNS-penetrant next-generation inhibitors, potentially supporting sentiment for competing ALK franchise assets.
Primarily US regulatory-driven sentiment for global pharma with oncology exposure; limited direct regional spillover beyond biotech/healthcare.
US FDA decision can affect global treatment sequencing discussions and trial enrollment expectations for ALK-positive NSCLC programs worldwide.
Counterpoint
Because the approval is accelerated and based on response rate in a single-arm trial, the market may discount the near-term value until confirmatory survival benefit is demonstrated in ALKAZAR.
Key entities
- drugNeladalkib
Oral ALK-targeted therapy granted FDA accelerated approval for previously treated ALK-positive NSCLC.
- clinical_trialALKOVE-1
Phase I/II single-arm trial supporting the approval, reporting confirmed ORR and duration of response.
- clinical_trialALKAZAR
Ongoing Phase III trial comparing neladalkib with alectinib as first-line therapy.
- companyGSK
Announced the FDA approval following its acquisition of Nuvalent, linking it to neladalkib’s development.




